Chris Thatcher to step down as President and CEO of Neuronetics

pharmafile | March 9, 2020 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing  

Neuronetics, Inc and Chris Thatcher, the President and CEO, have mutually agreed that he will step down from his positions in the company. He will provide transition services and advice to the company until 1 May 2020.

Thatcher will also step down as the director of the Neuronetics’ Board of Directors. The company has established an interim Office of the President to provide oversight and leadership during this transitional period until a new CEO is decided upon. It will be filled by Chief Financial Officer Steve Furlong and General Counsel Andrew Macan, who will also remain in their current positions.

The agreement was not the result of any violation of company policy, accounting irregularity or deterioration of the company.

Thatcher has led the company since late 2014 and helped oversee its $93.5 million Nasdaq IPO last June. On his departure he said: “It has been an incredible opportunity to have helped thousands of patients suffering with Major Depressive Disorder and their families renew their lives with NeuroStar.  I believe that the Company has a great future and is in excellent hands with a strong team that will continue to build on the important progress we have made.”


Related Content

No items found

Latest content